Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.

Paglino C, Procopio G, Sabbatini R, Bellmunt J, Schmidinger M, Bearz A, Bamias A, Melichar B, Imarisio I, Tinelli C, Porta C.

Anticancer Res. 2013 Nov;33(11):4999-5004.

PMID:
24222142
2.

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK.

Clin Genitourin Cancer. 2014 Aug;12(4):262-9. doi: 10.1016/j.clgc.2014.03.002. Epub 2014 Mar 14.

PMID:
24795159
3.

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.

Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24.

PMID:
20884115
4.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.

Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4.

5.

Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.

Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hörmann K, Schultz JD.

Anticancer Res. 2015 Apr;35(4):1951-9.

PMID:
25862847
6.

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.

Miyake H, Kusuda Y, Harada K, Sakai I, Fujisawa M.

Int J Clin Oncol. 2013 Feb;18(1):81-6. doi: 10.1007/s10147-011-0347-7. Epub 2011 Nov 18.

PMID:
22095244
7.

Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.

Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.

Curr Med Res Opin. 2016;32(4):741-7. doi: 10.1185/03007995.2016.1140028. Epub 2016 Jan 25.

PMID:
26744781
8.

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20.

9.

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21.

PMID:
21802830
10.

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.

Levy A, Menard J, Albiges L, Loriot Y, Di Palma M, Fizazi K, Escudier B.

Eur J Cancer. 2013 May;49(8):1898-904. doi: 10.1016/j.ejca.2013.02.003. Epub 2013 Mar 13.

PMID:
23490648
11.

Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.

Maute L, Grünwald V, Weikert S, Kube U, Gauler T, Kahl C, Burkholder I, Bergmann L.

J Cancer Res Clin Oncol. 2014 May;140(5):823-7. doi: 10.1007/s00432-014-1610-x. Epub 2014 Feb 21.

PMID:
24556802
12.

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.

Ambring A, Björholt I, Lesén E, Stierner U, Odén A.

Med Oncol. 2013 Mar;30(1):331. doi: 10.1007/s12032-012-0331-8. Epub 2012 Dec 18.

13.

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.

Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J.

Ann Oncol. 2012 Feb;23(2):395-401. doi: 10.1093/annonc/mdr065. Epub 2011 May 2.

PMID:
21536664
14.

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.

Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E.

BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23.

15.

Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.

Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A, Paraskevopoulos P, Dimopoulos M, Papazisis K.

Med Oncol. 2012 Jun;29(2):750-4. doi: 10.1007/s12032-010-9815-6. Epub 2011 Jan 30.

PMID:
21279702
16.

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8.

PMID:
24321257
17.

Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.

Chen CC, Hess GP, Liu Z, Gesme DH, Agarwala SS, Garay CC, Hill JW, Guo A.

Clin Genitourin Cancer. 2012 Dec;10(4):256-61. doi: 10.1016/j.clgc.2012.04.006. Epub 2012 Jun 7.

PMID:
22682982
18.

Sequential sorafenib and sunitinib for renal cell carcinoma.

Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B.

J Urol. 2009 Jul;182(1):29-34; discussion 34. doi: 10.1016/j.juro.2009.02.119. Epub 2009 May 17.

PMID:
19447417
19.

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D.

Eur J Cancer. 2013 Mar;49(5):1027-31. doi: 10.1016/j.ejca.2012.10.009. Epub 2012 Nov 6.

PMID:
23140824
20.

[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].

Siebels M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H; Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT).

Urologe A. 2011 Sep;50(9):1110-7. doi: 10.1007/s00120-011-2553-3. German.

PMID:
21559917

Supplemental Content

Support Center